BlinkLab Investor Centre
Stay informed with our latest ASX disclosures, investor material, and updates on BlinkLab's clinical and regulatory progress
The BlinkLab Pipeline
Below you find the latest version of our product pipeline. Any updates on our progress you will read in the news & announcement section.
Studies
Pilot Study
Study
Read BlinkLab's Latest Announcements
%20SMALL.jpg)
Awesome! You're now signed up.
You will receive our newsletter. You can opt out via the newsletter.
BlinkLab in the Media
Research Analyst Coverage
Independent investment analysis and research reports covering BlinkLab, provided by third-party analysts.
November 2025
Outstanding USA Pilot Results Set the Path for 2026 FDA Clearance
October 2025
Bioshares, Australia's Independent Biotech Investment Resource
October 2024
Lodge Partners sees 430% upside for Blinklab, developer of smartphone autism test
October 2024
Lodge Partners Initiation Research Report BlinkLab Ltd (ASX:BB1) ASD & ADHD
March 2024
Bioshares, Australia’s Independent Biotech Investment Resource
BlinkLab in the Media
Read the latest media coverage of BlinkLab's most recent clinical and corporate developments.
.jpeg)
.png)
"For me, it's gratifying to apply neuroscience for improving autism and ADHD diagnosis and care."
Dr. Henk-Jan Boele, co-founder of BlinkLab, leads a team of neuroscientists, medical doctors, and software developers to bring this mission to life. Founded as a Princeton University startup in 2021, BlinkLab went public on the ASX (ASX:BB1) in April 2024 and is now seeking FDA clearance for its first two diagnostic products:
BlinkLab Dx 1 – Diagnostic Aid Supporting Autism Assessment
FDA 510(k) Regulatory Program Currently Underway
BlinkLab Dx 2 – Diagnostic Aid Supporting ADHD Assessment
Clinical Feasibility Studies Currently in Preparation
(Co-Founder, Managing Director & CEO)
Investor Relations
Are you an active investor or a current BlinkLab shareholder?
We would love to hear from you, and are available to answer any questions you might have about the company and our mission.
Use this form to be redirected to our investor relations team, or you can reach out to BlinkLab's leaders using the contact details below.
Thank you!
Your submission has been received!